NeuroPace, Inc.
US ˙ NasdaqGM ˙ US6412881053

SecurityNPCE / NeuroPace, Inc.
InstitutionQube Research & Technologies Ltd
Latest Disclosed Ownership186,189 shares
Latest Disclosed Value $ 2,448,385
Qube Research & Technologies Ltd reports 6.44% decrease in ownership of NPCE / NeuroPace, Inc.

On May 15, 2026 - Qube Research & Technologies Ltd filed a 13F-HR form disclosing ownership of 186,189 shares of NeuroPace, Inc. (US:NPCE) valued at $2,448,385 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 198,997 shares of NeuroPace, Inc.. This represents a change in shares of -6.44% during the quarter. The current value of the position is $3,038,604 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NEUROPACE COM 641288105 186,189 -12,808 -6.44 2,448 -20.31 0.0027
2026-02-17 2025-12-31 13F NEUROPACE COM 641288105 198,997 -14,776 -6.91 3,073 39.38 0.0031
2025-11-14 2025-09-30 13F NEUROPACE COM 641288105 213,773 101,136 89.79 2,204 75.76 0.0023
2025-08-14 2025-06-30 13F NEUROPACE COM 641288105 112,637 48,175 74.73 1,255 58.33 0.0013
2025-05-15 2025-03-31 13F NEUROPACE COM 641288105 64,462 64,462 792 0.0009
2025-02-14 2024-12-31 13F NEUROPACE COM 641288105 0 -10,573 -100.00 0 -100.00
2024-11-14 2024-09-30 13F NEUROPACE COM 641288105 10,573 1,740 19.70 74 10.61 0.0001
2024-08-14 2024-06-30 13F NEUROPACE COM 641288105 8,833 -36,385 -80.47 67 -88.93 0.0001
2024-05-14 2024-03-31 13F NEUROPACE COM 641288105 45,218 19,016 72.57 597 120.74 0.0009
2024-02-13 2023-12-31 13F NEUROPACE COM 641288105 26,202 23,803 992.21 270 1,073.91 0.0005
2023-11-13 2023-09-30 13F NEUROPACE COM 641288105 2,399 2,399 23 0.0001
2022-05-09 2022-03-31 13F NEUROPACE COM 641288105 0 -19,086 -100.00 0 -100.00
2022-02-10 2021-12-31 13F/A-1 NEUROPACE COM 641288105 19,086 19,086 192 0.0015
2022-02-01 2021-12-31 13F NEUROPACE COM 641288105 19,086 19,086 192 0.0015
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.